Adverum Biotechnologies Inc
ADVM2.370USD
+0.050+2.16%
Market hours （ET）Quotes delayed by 15 min
49.19MMarket Cap
LossP/E TTM
More Details of Adverum Biotechnologies Inc Company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Company Info
Ticker SymbolADVM
Company nameAdverum Biotechnologies Inc
IPO dateJul 31, 2014
CEODr. Laurent Fischer, M.D.
Number of employees155
Security typeOrdinary Share
Fiscal year-endJul 31
Address100 Cardinal Way
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94063
Phone16506491004
Websitehttps://adverum.com/
Ticker SymbolADVM
IPO dateJul 31, 2014
CEODr. Laurent Fischer, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.39%
Investment Advisor/Hedge Fund
15.91%
Individual Investor
12.20%
Private Equity
6.88%
Venture Capital
5.02%
Hedge Fund
2.57%
Research Firm
2.54%
Corporation
0.87%
Bank and Trust
0.12%
Other
7.51%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
192
19.32M
92.50%
-3.22M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
2023Q1
309
6.72M
66.88%
-3.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
3.06M
14.64%
+315.21K
+11.49%
May 19, 2025
TCG Crossover Management, LLC
1.80M
8.6%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.76M
8.43%
--
--
Mar 31, 2025
Principia Wealth Advisory, LLC
1.70M
8.12%
+366.15K
+27.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.31M
6.29%
-57.92K
-4.22%
Mar 31, 2025
Stern (Augustus)
1.12M
5.35%
+1.12M
--
Oct 29, 2024
Frazier Life Sciences Management, L.P.
1.07M
5.12%
--
--
Mar 31, 2025
Rush (Ryan Bradford)
1.05M
5.03%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
1.03M
4.93%
-1.76K
-0.17%
Mar 31, 2025
5AM Ventures
541.67K
2.59%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Date
Type
Ratio
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
